ALNY
Alnylam Pharmaceuticals, Inc.
NMS
$282.85
-6.54
(-2.26%)
Pullback · -1.19σ
Valuation
Market cap
$37.8B
P/E (ttm)
70.9
Forward P/E
20.5
Beta (5y)
0.27
Shares out
133.5M
Div yield
—
Profitability & returns
ROE
90.4%
Net margin
12.6%
FCF margin
4.8%
Debt / equity
2.76
Trading information
Last price
$282.85
Day range
$282.85 – $282.85
52-wk range
$281.77 – $427.05
Avg volume
1.1M
RSI (2)
8.6
TAO zone
Pullback
Company
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Next earnings
2026-07-30
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and…